EGFR and lung adenocarcinoma: These findings align with those of our study, in which patients with bone metastases from lung adenocarcinoma with EGFR 19del mutation had longer-term control of both primary tumors and bone metastases, with PFS of 18 and 22 months and even longer OS after targeted therapy with osimertinib, following different treatments such as chemotherapy, radiotherapy, and surgery.